US Army #ProstateCancer Research Program will fund $110 million in research grants in FY2023 - several RFAs have been announced and will support impactful research to reduce death and suffering from prostate cancer #pcsm cdmrp.health.mil/funding/pcrp

The Prostate Cancer Foundation Coffey-Holden #ProstateCancer Academy Meeting, #PCFAcademy starts tomorrow! This is our 10th year of this extraordinary discussion-oriented conference, focusing on the most critical & cutting-edge research that will accelerate new treatment strategies for patients!

It was a lot of fun working with you both on this review on Androgen Targeting in Prostate Cancer Journal of Clinical Oncology! Nima Sharifi Sylvester Comprehensive Cancer Center Charlie Dai Dana-Farber Masonic Cancer Center, University of Minnesota

We're excited to announce the invited speakers for this year's Great Lakes Nuclear Receptor Conference! Abstracts now being accepted; for more information go to roswellpark.org/GLNRC2023

🗒️ #JCO #Review: Androgen signaling axis targeting in #ProstateCancer and molecular basis of response and resistance #PCSM ➡️ fal.cn/3Apar Nima Sharifi Charlie Dai Scott Dehm

Co-evolution of AR gene copy number and structural complexity in endocrine therapy resistant prostate cancer. 𝙉𝘼𝙍 𝘾𝙖𝙣𝙘𝙚𝙧. Scott Dehm #ProstateCancer bit.ly/45SpViB

Check out our latest work showing ecDNA as a way that prostate cancer cells can amplify and structurally diversify the AR gene in advanced prostate cancers! Great collaboration with UW Urology Felix Feng UCSF Helen Diller Family Comprehensive Cancer Ctr Ben Raphael Masonic Cancer Center, University of Minnesota academic.oup.com/narcancer/arti…

Congratulations Scott Dehm and Andrej from UMN Pharmacology and MPaT

How far have we come in over 200 years of work in prostate cancer? See the timeline below from Charlie Dai for an amazing distillation Journal of Clinical Oncology. Now we are here #PCFRetreat23 to take the next steps! PCF Science ascopubs.org/doi/full/10.12…

This means so much to me. The first truly new direction I took as a professor. It began in 2017 when my first student Preston Crowell figured out how to metabolically profile basal and luminal cells. It's grown into the paper I'm most proud of in my career nature.com/articles/s4155…

🔥New study from lab that found ATGL, a mediator of intracellular lipolysis, is 📈in mCRPC, regulated by #CAMKK2 #AMPK, and a druggable target for advanced #prostatecancer. Both lipolytic and non-lipolytic roles of ATGL are key. MD Anderson Cancer Center Cancer Research bit.ly/3NfF5az

Its out! Check out our latest review article “Androgen receptor and estrogen receptor variants in prostate and breast cancers” in the Journal of Steroid Biochemistry and Molecular Biology 🧫 🧬 authors.elsevier.com/a/1izxk3QIyUNZ…

Hot off the press, Emmanuel Antonarakis and team Caris Precision Oncology Alliance Translational Research group: Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target across Human Malignancies, in Cancer Research Communications aacrjournals.org/cancerrescommu…

“You don’t need to know how to do everything. You need a vision and a sustainable team that continues to pay it forward.” Felix Feng

Grateful for the 260 in-person attendees #FengSymposium & hundreds more around the world sending love and admiration for the greatest GU scientist, translator, clinical trialist, entrepreneur, mentor, and friend Felix Feng & thank you Josh Lang for co-organizing!

#FengSymposium24 honoring our dear Felix Feng organized by Paul Nguyen & Josh Lang with 250+ close friends.

Susan Halabi representing DCI Center for Prostate & Urologic Cancers at #ASCO24 presenting our Alliance for Clinical Trials in Oncology clinical genetic model using the Scott Dehm AR-ctDETECT ctDNA assay. The new Halabi+ model! Duke Cancer

Susan Halabi ⁦Duke Cancer⁩ presents data on genetic perturbations and outcomes in the Alliance RCT of enz +/- abi and the findings are really interesting from a clinical biology standpoint! ⁦ASCO⁩ #asco24 ⁦PCF Science⁩ Additional kudos to ⁦Scott Dehm⁩!

The next-gen Halabi model. ctDNA content, AR enhancer gains, and other genomic factors add prognostic impact beyond clinical factors. Congrats to the Scott Dehm group for serving as the central ctDNA lab for this trial. Scott Dehm

Susan Halabi and Andrew Armstrong discuss new AR-ctDETECT assay and clinical-genetic prognostic model of OS in men w mCRPC, building on prior clinical models to develop new risk groups that teach us about biology & patient outcomes DCI Center for Prostate & Urologic Cancers Alliance for Clinical Trials in Oncology Scott Dehm